Literature DB >> 23651816

A critical challenge: dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction.

Lian R Gao1, Xue T Pei, Qing A Ding, Yu Chen, Ning K Zhang, Hai Y Chen, Zhi G Wang, Yun F Wang, Zhi M Zhu, Tian C Li, Hui L Liu, Zi C Tong, Yong Yang, Xue Nan, Feng Guo, Jian L Shen, Yan H Shen, Jian J Zhang, Yu X Fei, Hong T Xu, Li H Wang, Hai T Tian, Da Q Liu, Ye Yang.   

Abstract

BACKGROUND: Previous studies showed improvement in heart function by injecting bone marrow mesenchymal stem cells (BMSCs) after AMI. Emerging evidence suggested that both the number and function of BMSCs decline with ageing. We designed a randomized, controlled trial to further investigate the safety and efficacy of this treatment.
METHODS: Patients with ST-elevation AMI undergoing successful reperfusion treatment within 12 hours were randomly assigned to receive an intracoronary infusion of BMSCs (n=21) or standard medical treatment (n=22) (the numbers of patients were limited because of the complication of coronary artery obstruction).
RESULTS: There is a closely positive correlation of the number and function of BMSCs vs. the cardiac function reflected by LVEF at baseline (r=0.679, P=0.001) and at 12-month follow-up (r=0.477, P=0.039). Six months after cell administration, myocardial viability within the infarct area by 18-FDG SPECT was improved in both groups compared with baseline, but no significant difference in the BMSCs compared with control groups (4.0±0.4% 95%CI 3.1-4.9 vs. 3.2±0.5% 95%CI 2.1-4.3, P=0.237). 99mTc-sestamibi SPECT demonstrated that myocardial perfusion within the infarct area in the BMSCs did not differ from the control group (4.4±0.5% 95%CI 3.2-5.5 vs. 3.9±0.6% 95%CI 2.6-5.2, P=0.594). Similarly, LVEF after 12 and 24 months follow-up did not show any difference between the two groups. In the BMSCs group, one patient suffered a serious complication of coronary artery occlusion during the BMSCs injection procedure.
CONCLUSIONS: The clinical benefits of intracoronary injection of autologous BMSCs in acute STEMI patients need further investigation and reevaluation.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Acute myocardial infarction; Bone marrow mesenchymal stem cells; Intracoronary injection

Mesh:

Year:  2013        PMID: 23651816     DOI: 10.1016/j.ijcard.2013.04.112

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  37 in total

1.  Mesenchymal stromal cells and ischemic heart disease: hitting the target?

Authors:  Donald G Phinney
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

Review 2.  Vascular stem cells-potential for clinical application.

Authors:  Sadie C Slater; Michele Carrabba; Paolo Madeddu
Journal:  Br Med Bull       Date:  2016-06       Impact factor: 4.291

Review 3.  Adult Bone Marrow Cell Therapy for Ischemic Heart Disease: Evidence and Insights From Randomized Controlled Trials.

Authors:  Muhammad R Afzal; Anweshan Samanta; Zubair I Shah; Vinodh Jeevanantham; Ahmed Abdel-Latif; Ewa K Zuba-Surma; Buddhadeb Dawn
Journal:  Circ Res       Date:  2015-07-09       Impact factor: 17.367

4.  Comparing the effect of bone marrow mono-nuclear cells with mesenchymal stem cells after acute myocardial infarction on improvement of left ventricular function: a meta-analysis of clinical trials.

Authors:  Alireza Hosseinpour; Fatemeh Kheshti; Asma Kazemi; Armin Attar
Journal:  Stem Cell Res Ther       Date:  2022-05-16       Impact factor: 8.079

5.  Route of Delivery Modulates the Efficacy of Mesenchymal Stem Cell Therapy for Myocardial Infarction: A Meta-Analysis of Preclinical Studies and Clinical Trials.

Authors:  Anthony J Kanelidis; Courtney Premer; Juan Lopez; Wayne Balkan; Joshua M Hare
Journal:  Circ Res       Date:  2016-12-28       Impact factor: 17.367

6.  Safety of intracoronary infusion of 20 million C-kit positive human cardiac stem cells in pigs.

Authors:  Matthew C L Keith; Xian-Liang Tang; Yukichi Tokita; Qian-Hong Li; Shahab Ghafghazi; Joseph Moore Iv; Kyung U Hong; Brandon Elmore; Alok Amraotkar; Brian L Ganzel; Kendra J Grubb; Michael P Flaherty; Gregory Hunt; Bathri Vajravelu; Marcin Wysoczynski; Roberto Bolli
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

7.  Timing for intracoronary administration of bone marrow mononuclear cells after acute ST-elevation myocardial infarction: a pilot study.

Authors:  Rongchong Huang; Kang Yao; Aijun Sun; Juying Qian; Lei Ge; Yiqi Zhang; Yuhong Niu; Keqiang Wang; Yunzeng Zou; Junbo Ge
Journal:  Stem Cell Res Ther       Date:  2015-05-29       Impact factor: 6.832

8.  Intracoronary infusion of Wharton's jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial.

Authors:  Lian R Gao; Yu Chen; Ning K Zhang; Xi L Yang; Hui L Liu; Zhi G Wang; Xiao Y Yan; Yu Wang; Zhi M Zhu; Tian C Li; Li H Wang; Hai Y Chen; Yun D Chen; Chao L Huang; Peng Qu; Chen Yao; Bin Wang; Guang H Chen; Zhong M Wang; Zhao Y Xu; Jing Bai; Di Lu; Yan H Shen; Feng Guo; Mu Y Liu; Yong Yang; Yan C Ding; Ye Yang; Hai T Tian; Qing A Ding; Li N Li; Xin C Yang; Xiang Hu
Journal:  BMC Med       Date:  2015-07-10       Impact factor: 8.775

9.  Myocardial regeneration strategy using Wharton's jelly mesenchymal stem cells as an off-the-shelf 'unlimited' therapeutic agent: results from the Acute Myocardial Infarction First-in-Man Study.

Authors:  Piotr Musialek; Adam Mazurek; Danuta Jarocha; Lukasz Tekieli; Wojciech Szot; Magdalena Kostkiewicz; R Pawel Banys; Malgorzata Urbanczyk; Andrzej Kadzielski; Mariusz Trystula; Jacek Kijowski; Krzysztof Zmudka; Piotr Podolec; Marcin Majka
Journal:  Postepy Kardiol Interwencyjnej       Date:  2015-06-22       Impact factor: 1.426

Review 10.  Bone marrow-derived mesenchymal stem cells for the treatment of heart failure.

Authors:  Takuya Narita; Ken Suzuki
Journal:  Heart Fail Rev       Date:  2015-01       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.